Solasia Pharma K.K. (TYO:4597)

Japan flag Japan · Delayed Price · Currency is JPY
34.00
+1.00 (3.03%)
Apr 28, 2026, 3:30 PM JST
6.25%
Market Cap 9.28B
Revenue (ttm) 429.00M
Net Income (ttm) -876.00M
Shares Out 273.01M
EPS (ttm) -3.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 51,701,000
Average Volume 66,359,210
Open 33.00
Previous Close 33.00
Day's Range 33.00 - 35.00
52-Week Range 27.00 - 48.00
Beta 1.19
RSI 48.35
Earnings Date May 14, 2026

About Solasia Pharma K.K.

Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical t... [Read more]

Sector Healthcare
Founded 2006
Employees 22
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4597
Full Company Profile

Financial Performance

In 2025, Solasia Pharma K.K.'s revenue was 429.00 million, an increase of 35.76% compared to the previous year's 316.00 million. Losses were -876.00 million, -54.87% less than in 2024.

Financial Statements

News

There is no news available yet.